FDA approves ConTIPI Medical ’ s ProVate pelvic organ prolapse treatment

ConTIPI today announced FDA approval for its ProVate device.
ProVate is designed to treat pelvic organ prolapse in women. It’s a disposable, non-invasive treatment option that supports lateral vaginal walls and mechanically prevents cervical/vault descent, according to the company. It blocks further descent of the anterior/posterior walls within its central piece and is available in six different sizes.
“For many years we have been working to promote pelvic floor solutions and products that will help every woman conduct a normal life and fully control her medical condition,” founder and CEO Elan Ziv said in a press release. “This is an innovative, groundbreaking product enabling women to control their medical problem and we assume that the product will soon be available to millions of women worldwide who would be interested in treatment.”
The ProVate device won CE Mark approval in 2017 after being in development for more than four years.

Source: Mass Device - July 9, 2019 Category: Medical Devices Authors: Danielle Kirsh Tags: Food & Drug Administration (FDA) Women's Health ConTIPI Source Type: news